This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

4 Companies That Are Bleeding Cash

Rite Aid

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Also on the retail front, Rite Aid (RAD - Get Report) plays a dangerous game. The drugstore chain has been lumbering under a massive debt load, preserving cash while rivals such as Walgreen (WAG) and CVS Caremark (CVS) invest in growth.

Rite Aid's prospects have actually improved a bit lately: Decent recent sales trends have pushed the stock up nearly 50% since October to a recent $1.30. Still, considerable stress remains on this business model. As of the end of November 2011, Rite Aid had $150 million in cash, and more than $6 billion in debt. The company pays out more than $500 million in interest to its bondholders every year. Trouble is, that's the size of the company's cash flow so profits don't go to the balance sheet, they go to the bondholders.

Rite Aid recently announced an impressive 3.6% jump in December same-store sales. Yet almost all of that gain was attributed to a spike in pharmacy sales as several new popular generic drugs hit the market (drug store chains have a higher percentage of exposure to generics while pharmacy benefit managers are more likely to sell branded drugs). Sales growth away from the pharmacists' counter was anemic.

Rite Aid is unlikely to wrestle with bankruptcy fears in the very near-term, but the retailer simply can't afford to move back to negative same-store sales trends. If that happens, the $6 billion debt load would start to be in sharp focus for short-sellers.

Rite Aid is rated D sell by TheStreet Ratings.
3 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
ACHN $6.14 3.00%
SHLD $15.11 -0.92%
RAD $7.79 0.39%
KIOR $0.01 -3.45%
AAPL $95.23 0.25%


Chart of I:DJI
DOW 16,025.61 +11.23 0.07%
S&P 500 1,867.52 +15.31 0.83%
NASDAQ 4,334.5510 +65.7880 1.54%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs